The White House said Friday it’s adding three drugs for diabetes and lung disease to the self-pay platform TrumpRx, as the ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Lilly’s experimental drug met endpoints for blood-sugar level reduction and weight loss at trial.

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

March 20 () - Taking GLP-1 drugs for diabetes has been shown to lower the risk of adverse heart events, but a new analysis ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

A new study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with Type 2 ...

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness ...

A new study suggests that almost half of people stopping GLP-1 weight-loss drugs may keep the weight off. However, many of these people continued other forms of treatment after stopping GLP-1 drugs.

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.